XML 47 R32.htm IDEA: XBRL DOCUMENT v3.26.1

Business Segment Information (Tables)

3 Months Ended

Mar. 28, 2026

Segment Reporting [Abstract]

Schedule of Business Segment Information

2026

			Three months ended March 28, 2026
(In millions)			Life Sciences Solutions			Analytical Instruments			Specialty Diagnostics			Laboratory Products and Biopharma Services			Total
Revenues
Revenues from external customers			$	2,219		$	1,667		$	1,124		$	5,995		$	11,005
Intersegment revenues			417			49			18			41			524
			2,636			1,716			1,142			6,036			11,529
Elimination of intersegment revenues															(524)
Consolidated revenues															$	11,005
Segment Income
Cost of revenues			1,004			876			657			4,757
Selling, general, and administrative expenses			496			313			177			597
Research and development expenses			131			139			44			15
Other segment items			50			34			(49)			(110)
Segment income			954			355			313			778			2,399
Unallocated amounts
Cost of revenues adjustments															(14)
Selling, general and administrative expenses adjustments															(43)
Restructuring and other costs															(49)
Amortization of acquisition-related intangible assets															(430)
Interest income															233
Interest expense															(354)
Other income/(expense)															(9)
Consolidated income before income taxes															$	1,734

(In millions)			Unallocated amounts			Life Sciences Solutions			Analytical Instruments			Specialty Diagnostics			Laboratory Products and Biopharma Services			Consolidated
Segment assets			$	98,434		$	3,490		$	3,104		$	1,332		$	6,921		$	113,281
Purchases of property, plant and equipment			28			20			36			35			259			376
Depreciation of property, plant and equipment			—			70			26			24			186			306

2025

			Three months ended March 29, 2025
(In millions)			Life Sciences Solutions			Analytical Instruments			Specialty Diagnostics			Laboratory Products and Biopharma Services			Total
Revenues
Revenues from external customers			$	1,954		$	1,677		$	1,130		$	5,603		$	10,364
Intersegment revenues			387			41			18			37			482
			2,341			1,718			1,148			5,640			10,846
Elimination of intersegment revenues															(482)
Consolidated revenues															$	10,364
Segment Income
Cost of revenues			855			835			679			4,410
Selling, general, and administrative expenses			468			313			171			588
Research and development expenses			139			137			45			13
Other segment items			45			33			(51)			(103)
Segment income			834			399			304			731			2,269
Unallocated amounts
Cost of revenues adjustments															(11)
Selling, general and administrative expenses adjustments															(14)
Restructuring and other costs															(98)
Amortization of acquisition-related intangible assets															(429)
Interest income															203
Interest expense															(303)
Other income/(expense)															3
Consolidated income before income taxes															$	1,620

(In millions)			Unallocated amounts			Life Sciences Solutions			Analytical Instruments			Specialty Diagnostics			Laboratory Products and Biopharma Services			Consolidated
Segment assets			$	85,272		$	3,018		$	2,986		$	1,298		$	6,467		$	99,041
Purchases of property, plant and equipment			36			43			44			33			205			362
Depreciation of property, plant and equipment			—			59			24			22			172			276

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration